Aarti Drugs Limited – Investor Presentation Summary
Key Operational Highlights
- Volume growth continued over past 5 years despite industry-wide oversupply and price erosion from Chinese dumping
- Sayakha facility operated at nearly 65% utilization during Q1 FY27, progressively contributing to backward integration capabilities
- Brownfield and adjacent plot developments in Baddi, Himachal Pradesh underway to double oral solid dosage (OSD) production capacity
- 9 API manufacturing units with installed capacity of 48,204 MTPA
- Formulation capacity: 3 billion tablets and 300 million capsules
- Specialty chemicals capacity: 34,308 MTPA
Key drivers of operational performance: Volume growth, improved realizations across API & Specialty Chemicals portfolio, disciplined execution, operational efficiencies, product mix optimization
Segment-wise Performance
- API segment contributes ~92% of total revenues with 50+ molecules across therapeutic categories including antibiotics, antiprotozoals, anti-inflammatories, anti-diabetics, and anti-fungals
- Largest global manufacturer of 5 molecules
- Formulations business operates through wholly owned subsidiary Pinnacle Life Science Private Limited
- Therapeutic revenue split represents split within the API segment including sales to Pinnacle Life Science
Financial Highlights
Revenue: ₹703.6 crore
EBITDA: ₹96.9 crore
PAT: ₹50.1 crore
EPS: ₹5.49
Margins: Gross Margin 39.3%, EBITDA Margin 13.8%, PAT Margin 7.1%
YoY comparison: Revenue up 19%, EBITDA up 30%, PAT down 7% (Q1 FY26 tax included ₹15 crore principal tax refund)
QoQ comparison: Revenue down 2%, EBITDA flat, PAT down 9%
Drivers of financial performance: Volume growth, improved realizations, operational efficiencies, product mix optimization
Comparison to market estimates: Not Specified
Key Risks: Uncertain and volatile global environment, raw material price fluctuations
Geographical Revenue Split
Domestic vs Export/Regional Revenue: Not Specified
Regional Breakdown: Not Specified
Balance Sheet Snapshot
Net Debt/Equity: Not Specified
Reserves: ₹1,457.6 crore (FY26)
Current Assets/Liabilities: Current Assets ₹1,460.6 crore, Current Liabilities Not Specified (FY26)
Working Capital/Leverage Metrics: Not Specified
Financial Health Insights: Strong net operating cashflow generation, low leverage provides Balance Sheet strength
Capex & Cash Flow Health
Capital Expenditure: ₹600 crores capex complete over recent period
Free Cash Flow: Not Specified
Operating Cash Flow: Net Cash from Operating Activities ₹253.5 crore (FY26)
Net Debt Movement: Not Specified
Investment Rationale: Boosting capacity, margins, backward integration
Strategic & R&D Initiatives
Investments in Innovation: ₹200 crore invested over last 24 months for oncology development and pipeline growth; R&D spend ₹66 crores (FY26); Developing complex generics, semi-solids, oral liquids
Expected impact on growth: Deeper penetration into regulated markets with better realizations
Strategic Rationale: Expanding into new geographies, developing complex medicine categories, shifting toward specialized chemistry products with premium pricing
Industry Trends & Business Environment
Macro/Industry Trends: Indian pharmaceutical industry is largest global supplier of generic medicines (20% of global generic drug demand); Pharmaceutical exports grew to USD 30.5 billion in FY 2024–25 (9.4% YoY increase); India ranked third-largest API market in Asia-Pacific with 8% global market share
Impact on Company: Positioned to capitalize on growth opportunities through regulatory compliance and manufacturing capabilities
Management Commentary & Growth Outlook
Strategic Outlook: "We began FY27 with a strong operational and financial performance, driven by a mix of volume growth and improved realizations across our API & Speciality Chemicals portfolio and disciplined execution. The demand outlook for our product portfolio looks encouraging."
FY Guidance: Not Specified
Market Share Targets: Not Specified
Risks and Opportunities: Uncertain and volatile global environment; Continued focus on operational efficiencies and product mix; Investments in process optimization, capacity enhancement, backward integration
ESG Initiatives
Not Specified in provided data
Digital Transformation
Not Specified in provided data